Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: OX40 based therapeutics - Genentech

Drug Profile

Research programme: OX40 based therapeutics - Genentech

Alternative Names: Anti-OX40L; CD134; CTB OX40; CTB-134L

Latest Information Update: 17 Apr 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenova Group
  • Class Differentiation antigens; Membrane glycoproteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 26 Apr 2002 Genentech has signed a worldwide licensing agreement with Xenova
  • 22 Nov 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
  • 28 Jun 2001 Cantab Pharmaceuticals has been acquired by Xenova Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top